Korro Bio SVP sells 7,353 shares in plan trade

Korro Bio’s Senior Vice President, Finance sold 7,353 shares under a Rule 10b5-1 plan and continues to hold 16,241 unvested RSU-based shares vesting through 2028.

Rhea-AI Filing Summary

Korro Bio, Inc. (KRRO) reported that Senior Vice President, Finance Oliver Dolan sold a total of 7,353 shares of Common Stock on September 8–9, 2026 in open-market or private transactions made pursuant to a Rule 10b5-1 trading plan adopted on June 8, 2026.

The September 8 sale covered 7,347 shares at a weighted-average price of $13.5138 per share, with prices ranging from $13.50 to $13.595. The September 9 sale covered 6 shares at a weighted-average price of $13.6033, with prices ranging from $13.52 to $13.76. Following these transactions, Dolan’s holdings include 16,241 shares issuable upon settlement of unvested RSUs, consisting of 10,741 shares scheduled to vest on December 15, 2026, 2,750 on July 15, 2027, and 2,750 on July 15, 2028, each subject to maintaining a continuous Service Relationship.

Insider Trade Summary 10b5-1

Net Seller: 7,353 shares

Net Sell 2 txns

Insider Dolan Oliver

Role Senior Vice President, Finance

Sold 7,353 shs ($99K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F4, F3	6	$13.6033	$81.62
Sale	Common Stock F1, F2, F3	7,347	$13.5138	$99K

Holdings After Transaction: Common Stock — 16,246 shares (Direct)

Footnotes (4)

1. F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 8, 2026.
2. F2. The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions at prices ranging from $13.50 to $13.595, inclusive. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request.
3. F3. Includes 16,241 shares of common stock issuable upon settlement of restricted stock units (RSUs) that remain unvested, consisting of 10,741 shares that will vest on December 15, 2026, 2,750 shares that will vest on July 15, 2027, and 2,750 shares that will vest on July 15, 2028, in each case subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through each such date.
4. F4. The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions at prices ranging from $13.52 to $13.76, inclusive. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request.

Key Figures

Total shares sold: 7,353 shares Shares sold on September 8, 2026: 7,347 shares Weighted-average sale price on September 8, 2026: $13.5138 per share +5 more

8 metrics

Total shares sold 7,353 shares Common Stock sales reported for September 8–9, 2026

Shares sold on September 8, 2026 7,347 shares Open-market or private sale of Common Stock

Weighted-average sale price on September 8, 2026 $13.5138 per share Prices ranged from $13.50 to $13.595

Shares sold on September 9, 2026 6 shares Open-market or private sale of Common Stock

Weighted-average sale price on September 9, 2026 $13.6033 per share Prices ranged from $13.52 to $13.76

Unvested RSU-based shares 16,241 shares Shares of Common Stock issuable upon settlement of unvested RSUs

RSU vesting on December 15, 2026 10,741 shares Subject to maintaining a continuous Service Relationship

RSU vesting on July 15, 2027 and July 15, 2028 2,750 shares each date Unvested RSUs scheduled to vest in 2027 and 2028

Key Terms

Rule 10b5-1 trading plan, weighted-average price, restricted stock units (RSUs), Service Relationship

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted-average price financial

"The price reported in Column 4 is a weighted-average price"

Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.

restricted stock units (RSUs) financial

"Includes 16,241 shares of common stock issuable upon settlement of restricted stock units (RSUs)"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

Service Relationship technical

"subject to the reporting person maintaining a continuous Service Relationship"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Korro Bio (KRRO) disclose in this Form 4?

Korro Bio disclosed that Senior Vice President, Finance Oliver Dolan sold 7,353 shares of Common Stock on September 8–9, 2026 in open-market or private transactions.

Were the KRRO insider stock sales made under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Oliver Dolan on June 8, 2026.

At what prices did the Korro Bio (KRRO) insider sell shares?

On September 8, 2026, 7,347 shares were sold at a weighted-average price of $13.5138, with prices from $13.50 to $13.595. On September 9, 2026, 6 shares were sold at a weighted-average price of $13.6033, with prices from $13.52 to $13.76.

How many unvested RSUs does the Korro Bio (KRRO) insider still hold after these sales?

The reporting person’s holdings include 16,241 shares of Common Stock issuable upon settlement of unvested RSUs, subject to vesting conditions and a continuous Service Relationship.

What is the vesting schedule of the unvested RSUs for the KRRO insider?

The filing states that 10,741 RSU-based shares will vest on December 15, 2026, 2,750 on July 15, 2027, and 2,750 on July 15, 2028, each subject to the reporting person maintaining a continuous Service Relationship.

Does the Form 4 state the total common shares Dolan holds after the KRRO sales?

The Form 4 notes that post-transaction holdings include 16,241 unvested RSU-based shares. It does not state a total number of common shares held outright after the reported sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 04:06 PM Accepted by SEC EDGAR 09/10/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dolan Oliver

(Last) (First) (Middle)

C/O KORRO BIO, INC.

60 FIRST STREET, 2ND FLOOR, SUITE 250

(Street)

CAMBRIDGE MASSACHUSETTS 02141

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Korro Bio, Inc. [ KRRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior Vice President, Finance

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/08/2026		S(1)		7,347	D	$13.5138(2)	16,252(3)	D
Common Stock	09/09/2026		S(1)		6	D	$13.6033(4)	16,246(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 8, 2026.

2. The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions at prices ranging from $13.50 to $13.595, inclusive. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request.

3. Includes 16,241 shares of common stock issuable upon settlement of restricted stock units (RSUs) that remain unvested, consisting of 10,741 shares that will vest on December 15, 2026, 2,750 shares that will vest on July 15, 2027, and 2,750 shares that will vest on July 15, 2028, in each case subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through each such date.

4. The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions at prices ranging from $13.52 to $13.76, inclusive. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request.

	/s/ Jeffrey Cerio, Attorney-in-fact	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)